Loading patent…
AssigneesThe United States of America, as represented by the Secretary, Department of Health and Human Services, Thomas Jefferson University, University of Maryland, Baltimore
InventorsReed F. Johnson, Matthias Schnell, Lisa E. Hensley, Christoph Wirblich, Christopher M. Coleman, Matthew S. Frieman
Estimating the term…
The present disclosure provides methods and compositions for inducing an immune response that confers dual protection against infections by either or both of a rabies virus and a coronavirus, and/or which can be used therapeutically for an existing infection with rabies virus and/or a coronavirus to treat at least one symptom thereof and/or to neutralize or clear the infecting agents. In particular, the present disclosure provides a recombinant rabies virus vector comprising a nucleotide sequence encoding at least one coronavirus immunogenic glycoprotein fragment, as well as pharmaceutical compositions comprising the vaccine vectors.
A recombinant rabies virus vector comprising a nucleotide sequence encoding at least one immunogenic glycoprotein fragment comprising a C-terminal truncation of a spike protein of Middle East Respiratory Coronavirus (MERS-CoV) or Severe Acute Respiratory Syndrome Coronavirus (SARS-COV).
A live, replication-competent, rabies virus based vector expressing at least one immunogenic glycoprotein fragment comprising a C-terminal truncation of a spike protein of Middle East Respiratory Coronavirus (MERS-COV) or Severe Acute Respiratory Syndrome Coronavirus (SARS-COV).
A live, replication-deficient, rabies virus based vector expressing at least one immunogenic glycoprotein fragment comprising a C-terminal truncation of a spike protein of Middle East Respiratory Coronavirus (MERS-COV) or Severe Acute Respiratory Syndrome Coronavirus (SARS-COV).
Dependencies are inferred from the claim text.